SAN DIEGO, Sept. 26, 2017 /PRNewswire/ -- AltheaDx, Inc. ("AltheaDx" or the "Company"), a commercial stage molecular diagnostics company specializing in the field of personalized medicine, announced today that the results from its clinical trial have been accepted for publication by the Journal of Psychiatric Research (ISSN: 0022-3956).
The publication details the results of a prospective, randomized, blinded clinical trial that enrolled 685 patients from twenty clinical sites in the U.S. with providers specializing in Psychiatry, Internal Medicine, Obstetrics & Gynecology, and Family Medicine. A few highlights of the findings included patients diagnosed with severe depression, for whom response rates (p = 0.001; OR: 4.72 [1.93–11.52]) and remission rates (p = 0.02; OR: 3.54 [1.27–9.88]) were significantly higher in the pharmacogenetics-guided group as compared to the control group after 12 weeks of follow-up. In addition, patients in the experimental group diagnosed with anxiety showed a meaningful improvement in HAM-A scores at both 8 and 12 weeks (p = 0.02 and 0.02, respectively), along with higher response rates (p = 0.04; OR: 1.76 [1.03–2.99]). "This publication represents an important milestone in further demonstrating the benefits of our IDgenetix® test to both physicians and their patients," said Dr. Jorge Garces, President and Chief Executive Officer. "We are dedicated to bringing personalized medicine to the forefront of patient care and are committed to continuing our efforts to educate and innovate in this area. The findings of this study demonstrate not only the ability of IDgenetix® testing to improve patient outcomes, but also show physicians' willingness to incorporate our laboratory results as part of their medication management decisions. Follow on publications from this study are under review at this time and will highlight the economic benefits of these outcomes as we continue to work with payors to secure long-term reimbursement."
AltheaDx is a commercial stage molecular diagnostics company which focuses on enabling physicians, managed care organizations, pharmaceutical companies and other healthcare entities to make personalized therapeutic decisions for patients. AltheaDx's IDgenetix® pharmacogenetic testing portfolio addresses some of the most prevalent clinical conditions in the United States, including cardiovascular disease, neuropsychiatric disorders and pain. AltheaDx is a CAP-accredited, CLIA-certified laboratory located in San Diego, CA. For more information, visit www.altheadx.com.
Forward Looking Statements
This press release may contain forward-looking statements regarding the business strategy of AltheaDx. These statements relate to future events and involve known and unknown risks, uncertainties and other factors that could cause actual levels of activity or performance to differ materially from those expressed or implied by these forward looking statements. These statements reflect the views of AltheaDx as of the date of this press release with respect to future events and, except as required by law, it undertakes no obligation to update or revise publicly any forward looking statements, whether as a result of new information, future events or otherwise after the date of this press release.
CONTACT: Andrew Jackson, 858-224-7264, firstname.lastname@example.org
View original content:http://www.prnewswire.com/news-releases/altheadx-prospective-randomized-controlled-clinical-trial-demonstrates-significant-improvements-in-the-treatment-of-depression-and-anxiety-over-standard-of-care-300525484.html
SOURCE AltheaDx, Inc.